Prof. Dr. Ersin Özaslan

Tıbbi Onkoloji

  • 2016 – Erciyes Üniversitesi Tıp Fakültesi
    Tıbbi Onkoloji Uzmanlığı
  • 2012 – Erciyes Üniversitesi Tıp Fakültesi
    İç Hastalıkları Uzmanlığı
  • 2007 – İstanbul Üniversitesi İstanbul Tıp Fakültesi
    Tıp Doktoru

Prof. Dr. Ersin Özaslan

Tıbbi Onkoloji
  • 2018 – Günümüz – Acıbadem Sağlık Grubu
    Tıbbi Onkoloji Uzmanı
  • 2016 – 2018 – Kayseri Eğitim ve Araştırma Hastanesi
    Tıbbi Onkoloji Kliniği

Prof. Dr. Ersin Özaslan

Tıbbi Onkoloji
  • Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
    Journal of BUON, 2017; 22(4): 863–868.
  • Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
    Journal of Chemotherapy, 2016; 28(3): 230–234.
    doi:10.1179/1973947815Y.0000000039
  • Psychological distress and loneliness in caregiver of advanced oncological inpatients
    Journal of Health Psychology, 2016; 21(9): 1896–1906.
    doi:10.1177/1359105314567770
  • Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors
    European Journal of Gastroenterology & Hepatology, 2016; 28(7): 836–841.
    doi:10.1097/MEG.0000000000000619
  • Hepatic steatosis is associated with higher incidence of liver metastasis in patients with metastatic breast cancer
    Journal of BUON, 2015; 20(4): 963–969.
  • Predictive significance of VEGF and HIF-1α expression in patients with metastatic colorectal cancer receiving chemotherapy combinations with bevacizumab
    Asian Pacific Journal of Cancer Prevention, 2015; 16(14): 6149–6154.
    doi:10.7314/APJCP.2015.16.14.6149
  • Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple-negative breast cancer patients
    Journal of BUON, 2015; 20(6): 1432–1439.
  • Is late recurrence a predictive clinical marker for better sunitinib response in metastatic renal cell carcinoma patients?
    Clinical Genitourinary Cancer, 2015; 13(6): 548–554.
    doi:10.1016/j.clgc.2015.07.005
  • Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy
    Asian Pacific Journal of Cancer Prevention, 2014; 15(8): 3641–3644.
    doi:10.7314/APJCP.2014.15.8.3641
  • Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer
    Asian Pacific Journal of Cancer Prevention, 2014; 15(6): 2501–2504.
    doi:10.7314/APJCP.2014.15.6.2501
Tedavinizi Planlay?n Plan Your Treatment Plan Uw Behandeling